Rationale
Janus kinases (JAK) transduce multiple cytokine receptors reported to play an important role in asthma and COPD. VR588 is a selective and potent pan-JAK inhibitor suited to inhalation delivery and therefore may represent a new opportunity for the treatment of these conditions. These studies were designed to characterise the in-vitro kinase inhibition profile of VR588 and to determine its selectivity versus non-JAK kinases.
Methods
Comparison of kinase inhibitory activity was conducted in a non-cell (Z'Lyte™ Florescence assay) and in cell based assays using stimulation of human whole blood (IL-2 stimulated INFγ production and JAK1/JAK3 and pSTATa/b activation and IL-6 stimulated pSTAT3 to assess JAK1, JAK2 and Tyk2 activity).
VR588 potently inhibited JAK 1, 2, 3 and Tyk2 kinases in the non-cell based assay. Low nM potency was achieved against all JAK kinases.
Results I
In the same non-cell based assay VR588 showed poor inhibitory activity against non-JAK kinases including FLT3, PDGFB, JNK2 and Syk.
Results

II
Results III
This potent and broad JAK inhibition was confirmed in the cell based assays with inhibition of IL-2 stimulated INFγ, IL-2 stimulated pSTATa/b & IL-6 stimulated pSTAT3.
Results IV
The range of these demonstrated between 14 to 128 fold lower affinity than binding to Jak2.
Conclusion
VR588 represents a potent and balanced inhibitor of the JAKs and the lack of off-target effects mitigates the potential for unwanted kinase activity. These results suggest VR588 may have utility as a pharmacological treatment of asthma and COPD and have prompted the characterisation of absorption, distribution, metabolism, and excretion (ADME) and in-vivo efficacy via the inhaled route.
Results V
TREEspot TM visualisation of kinase binding, where larger circles indicate higher affinity binding.
In addition, the selectivity of VR588 (1mM) against a panel of 93 human kinases was assessed using a competitive displacement assay. VR588 displaced DNA-tagged kinase from its immobilised active site ligand; binding to the kinases was determined by quantitative PCR (KinomeSCAN™). 
